Press

Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Jul 7 • 5 min read

Revive Therapeutics Ltd. (OTCQB: RVVTF / CSE: RVV / FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced results of the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734) evaluating the safety and efficacy of oral Bucillamine in patients with mild to…

COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital

Jul 7 • 3 min read

COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that the Company has entered into a term loan agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million. “COMPASS is pleased to partner with Hercules for this source of non-dilutive financing to support our COMP360…

Filament Health To Supply Psilocybin for Recipients of the Canadian Institutes of Health Research Psilocybin Operating Grants

Jul 7 • 2 min read

Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical–stage natural psychedelic drug development company, today announced that it will supply psilocybin for two clinical trials which have received The Canadian Institutes of Health Research (CIHR) Operating Grants for Psilocybin-assisted Psychotherapy for Mental Health and Substance Use Disorders. The clinical trials will study…

Aion Therapeutic Announces Proposed Non-Brokered Private Placement Offering of Units

Jul 5 • 1 min read

Aion Therapeutic Inc. (CSE: AION) is pleased to announce that it plans to undertake a non-brokered private placement of up to 50,000,000 units (“Units”) to raise gross proceeds of up to $500,000.00 (the “Unit Offering”). The Units will be offered at a price of $0.01, with each Unit consisting of one common share (“Share”) and one half of one common…

Small Pharma Announces Management Team Change

Jul 5 • 3 min read

Small Pharma Inc. (TSXV: DMT / OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that Mr. Peter Rands, co-founder, Chief Innovation & Intellectual Property Officer and former Chief Executive Officer of the Company, has left his positions as an executive officer and director of the Company and…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435